Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Immuneering Stock (NASDAQ: IMRX) stock price, news, charts, stock research, profile.
Open7.700 | Close- |
Vol / Avg.6.847K / 97.184K | Mkt Cap220.651M |
Day Range7.420 - 7.700 | 52 Wk Range3.700 - 16.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.430 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-08 | Oppenheimer | Mark Breidenbach | Reiterates | OutperformOutperform | Maintains | - | 25.00 |
2023-08-07 | Chardan Capital | Geulah Livshits | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-08-04 | Morgan Stanley | Jeffrey Hung | Maintains | Equal-WeightEqual-Weight | Maintains | 14.00 | 14.00 |
2023-06-26 | Oppenheimer | Mark Breidenbach | Assumes | Outperform | Announces | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
IMRX | Immuneering | -2.46% | 220.7M |
RENB | Renovaro Biosciences | -2.6% | 238.9M |
IPHA | Innate Pharma | 2.99% | 222.2M |
CELC | Celcuity | -0.8% | 217.8M |
EGRX | Eagle Pharmaceuticals | 3.48% | 204.7M |
You can purchase shares of Immuneering (NASDAQ: IMRX) through any online brokerage.
Other companies in Immuneering’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Celcuity (NASDAQ:CELC), Eagle Pharmaceuticals (NASDAQ:EGRX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Immuneering (NASDAQ: IMRX) was reported by Oppenheimer on Tuesday, August 8, 2023. The analyst firm set a price target for 25.00 expecting IMRX to rise to within 12 months (a possible 231.56% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Immuneering (NASDAQ: IMRX) is $7.54 last updated Today at September 22, 2023 at 3:18 PM UTC.
There is no dividend information for Immuneering.
Immuneering’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Immuneering.
Immuneering is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.